Introduction
Sarcopenia, defined as low muscle mass due to aging or other disease processes [1] [2] [3] , can have detrimental health consequences, including functional impairment, disability, and death [4] [5] [6] . Although sarcopenia occurs with normal aging, chronic infections can exert particularly profound changes in metabolic health and further exacerbate loss of muscle mass over time.
Sarcopenia is prevalent in HIV infection and has been independently associated with worse health outcomes, including progression to AIDS and reduced survival [4, [7] [8] [9] [10] . Mechanisms for muscle mass loss in HIV might include systemic chronic inflammation, increased resting energy expenditure, antiretroviral therapy (ART)-related fat redistribution and metabolic syndrome, and the impact of HIV-associated comborbidities [7, 8, [11] [12] [13] [14] .
Viral hepatitis coinfection, present in up to 30% of HIVinfected patients [15] , may induce additional adverse nutritional and metabolic changes that exacerbate low muscle mass in HIV [16] [17] [18] [19] . It has been previously shown that chronic hepatitis C virus (HCV) infection is associated with low muscle mass both prior to and after the development of cirrhosis [20] [21] [22] . Further, severe depletion of muscle mass and other signs of malnutrition are associated with increased mortality in chronic viral hepatitis [21, 22] . Consequently, HIV/viral hepatitiscoinfected individuals might be at especially high risk of low muscle mass, and this condition may contribute to the adverse health outcomes and increased mortality observed in this population [23, 24] . However, no studies have evaluated low muscle mass in HIV/viral hepatitiscoinfected patients.
To address existing knowledge gaps, we determined if HIV/viral hepatitis coinfection was associated with low muscle mass compared with HIV-monoinfected, viral hepatitis-monoinfected, and uninfected persons. We hypothesized that coinfected individuals would be at the highest risk of low muscle mass among these groups. We also identified risk factors associated with low muscle mass among coinfected persons.
Methods

Study design and setting
We performed a cross-sectional study among participants in the Multicenter AIDS Cohort Study (MACS) and Women's Interagency HIV Study (WIHS). The MACS is composed of HIV-infected or at-risk MSM at four US sites (Baltimore, Maryland; Washington, District of Columbia; Chicago, Illinois; Los Angeles, California; and Pittsburgh, Pennsylvania) and has enrolled 7317 men since 1984. The WIHS, initiated in 1994, enrolled 4194
HIV-infected or at-risk women from six US centers (Bronx, New York; Brooklyn, New York; Chicago, Illinois; Los Angeles, California; San Francisco, California; and Washington, District of Columbia) during three recruitment waves (1994-1995, 2001-2002, and 2011-2012) . Participants in both cohorts attend semiannual study visits; complete questionnaires on demographics, medical history, and risk behaviors; undergo physical examinations with anthropometry; and provide blood samples for serological testing. Details about the MACS and WIHS have been previously reported [25] [26] [27] . Study procedures performed at each participating MACS and WIHS site underwent regulatory review, and all participants provided informed consent. This study was approved by the University of Pennsylvania Institutional Review Board.
Study participants
All participants in the MACS and WIHS were eligible for study inclusion if they were tested for HIV and viral hepatitis infections and had available anthropometric data. Viral hepatitis infection was defined by a positive hepatitis B virus (HBV) surface antigen (HBsAg) or detectable HCV RNA.
HIV/viral hepatitis-coinfected participants were included if they had positive HIVantibody, received ART (defined as three or more antiretroviral drugs from at least two different antiretroviral classes, with exceptions made for combinations of three nucleotide reverse transcriptase inhibitors that include abacavir or tenofovir [28] ) for at least 1 year after January 2000, and had a positive HBsAg or HCV RNA. HIV-monoinfected participants had positive HIV antibody, received ART for at least 1 year after January 2000, and negative HBsAg and HCV antibody. Viral hepatitis-monoinfected patients had positive HBsAg or HCV RNA, and negative HIV antibody and viral load. Uninfected participants had negative HIV antibody and viral load, negative HBsAg, and negative HCVantibody or undetectable HCV RNA.
We required all HIV-infected patients to have received ART for at least 1 year to avoid bias from differential treatment of HIV due to hepatitis or nutritional status and because substantial changes in body composition may occur in the first year after ART initiation [10, 29, 30] . We further required ART initiation after January 2000 to minimize exposure to nucleoside reverse transcriptase inhibitors, such as zidovudine (ZDV), didanosine (DDI), or stavudine (D4T), which are associated with peripheral lipoatrophy [31] [32] [33] .
The index date was defined as the first study visit between 2000 and 2013 in which participants met eligibility criteria. Participants were excluded if they had a diagnosis of malignancy (except nonmelanomatous skin cancers) or AIDS (CD4 þ cell count <200 cells/ml) on or prior to the index date, given well established associations between these conditions and low muscle mass [12, 14, [34] [35] [36] .
Main study outcome The primary study outcome was low muscle mass, defined by a mid-upper arm muscle circumference (MUAC) measurement below the 10th percentile for agematched and sex-matched reference values derived from healthy US adults in the National Health and Nutritional Examination Survey, 1970-1974 [37] . MUAC captures the loss of peripheral tissue stores of protein and muscle, has been used previously as a marker of low muscle mass in HIV and viral hepatitis populations [8, 20, 38, 39] , and has been independently associated with increased mortality [8, 9, 30, 40] . Use of anthropometric measurements to determine muscle mass is less likely to be subject to misclassification in chronic liver disease compared with other traditional measures of malnutrition, including BMI or serum markers (e.g. albumin and prealbumin) [41] . Further, reference values were derived using data from National Health and Nutrition Examination Study (NHANES) participants from 1970 to 1974 because it was hypothesized that the rise in BMI over the last halfcentury has been driven primarily by increased adiposity, which would be associated with higher MUAC values that would not necessarily reflect an increase in muscle mass over this time period [42] [43] [44] .
To confirm the validity of MUAC as a measure of low muscle mass for this study, we evaluated the correlation between MUAC and fat-free mass determined by singlefrequency bioelectrical impedance analysis (SF-BIA) among a subset of 1360 participants who underwent simultaneous anthropometry and SF-BIA testing. MUAC measurements correlated well with fat-free mass determined by SF-BIA in this study (rho ¼ 0.71; P < 0.001).
Data collection
Self-reported demographic and clinical data collected on or prior to the index date included age, sex, race, ethnicity, education level, active alcohol use, and IDU, and active and/or past use of ZDV, DDI, or D4T. BMI (kg/m 2 ) was obtained at physical examination.
Laboratory results collected at the same visit or the prior visit closest to the index date included aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, and HIV viral load (copies/ml). Nadir CD4 þ cell count, defined as the lowest recorded CD4 þ prior to ART initiation, was also collected.
Two noninvasive laboratory measures of liver fibrosis, the AST-to-platelet ratio index (APRI) and the fibrosis-4 (FIB-4) scores, were calculated [45] [46] [47] . APRI was determined as [(AST (U/l)/upper limit of normal of AST) Â 100/platelet count (10 9 cells/l); AST upper limit of normal ¼ 40 U/l] [47] . An APRI score more than 2.0 has been shown to accurately identify cirrhosis (defined as METAVIR stage F4 or Ishak fibrosis score >5), whereas APRI less than 0.5 indicates absent or minimal fibrosis [47] . FIB-4 was calculated as: [age (years) Â AST (U/l)]/ [platelet count (10 9 cells/l) Â (ALT (U/l) 1/2 )]. A FIB-4 score more than 3.25 identifies advanced hepatic fibrosis/ cirrhosis, whereas scores less than 1.45 indicate no or minimal fibrosis [45, 46] .
Statistical analyses
Patient characteristics were evaluated by HIV/viral hepatitis status. Differences between groups were assessed using Chi-squared tests for categorical data and Wilcoxon rank-sum tests for continuous data. We determined the prevalence and 95% confidence intervals (CIs) of low muscle mass by HIV/viral hepatitis status. Results were stratified by HIV suppression status (HIV RNA <400 copies/ml) among HIV-infected patients.
Multivariable logistic regression was used to determine the adjusted odds ratios (ORs) with 95% CIs of low muscle mass in HIV/viral hepatitis-coinfected patients compared with those with viral hepatitis alone, HIV alone, and uninfected persons, controlling for confounding variables in each comparison. Demographic and clinical variables were evaluated as potential confounders.
Confounders remained in the model if the unadjusted OR changed by at least 10% after adjustment for the candidate factor or if a variable was considered a priori to be clinically important. We assessed if there were differential relationships between HIV/viral hepatitis infection and low muscle mass by sex, but observed no statistical interaction between infection status and sex. To evaluate associations between viral hepatitis and low muscle mass in the absence of cirrhosis, we repeated analyses excluding patients with APRI more than 2.0. In a sensitivity analysis, we evaluated the association between viral hepatitis and low muscle mass after controlling for active and/or past use of ARTs implicated in lipodystrophy (i.e. ZDV, DDI, and D4T). Analyses were also stratified by type of viral hepatitis infection in exploratory analyses. To isolate the effect of HIV RNA on the relationship between viral hepatitis coinfection and low muscle mass, analyses were repeated among HIV-infected persons stratified by HIV suppression.
Multivariable logistic regression was then used to evaluate risk factors for low muscle mass in coinfected patients. Hypothesized risk factors included active alcohol consumption, active IDU, lower nadir CD4 þ cell count, lack of HIV RNA suppression, and advanced liver disease (APRI > 2.0; FIB-4 > 3.25).
To address the potential bias of missing data, multiple imputation by chained equations was used to perform 20 imputations with all variables, and the main study outcome was included in the model [48] . Results were combined across the 20 datasets to arrive at the usual imputation CIs that accounted for within-dataset and across-dataset variances [49] .
Results
Among 11 511 participants enrolled in the MACS (n ¼ 7317) and WIHS (n ¼ 4194), 7993 did not meet inclusion criteria (Fig. 1 ). The final sample included 3518 participants from the MACS (n ¼ 1948) and WIHS (n ¼ 1570), of whom 164 (5%) were HIV/viral hepatitiscoinfected, 223 (6%) were viral hepatitis-monoinfected, 1070 (30%) were HIV-monoinfected, and 2061 (59%) were uninfected. Chronic HCV accounted for the majority of viral hepatitis infections in the coinfected [n ¼ 124 (76%)] and viral hepatitis-monoinfected [n ¼ 189 (85%)] groups.
The characteristics of the patients are reported in Table 1 . HIV/viral hepatitis-coinfected participants were more commonly non-Hispanic black and less educated compared with all other participants. Uninfected participants had the highest proportion of active alcohol users, whereas IDU and diabetes mellitus were most prevalent among those with viral hepatitis monoinfection. Nadir CD4 þ cell count and HIV RNA levels were similar between the HIV/viral hepatitis-coinfected and HIV-monoinfected groups, although fewer coinfected individuals achieved HIV RNA levels less than 400 copies/ml. Median BMI, waist circumference, and MUAC measurements were lower in the coinfected than all other groups ( (Fig. 2) . Results were similar after exclusion of patients with cirrhosis by APRI (Fig. 2) . There was no statistical interaction between sex and infection status in any of our analyses (P > 0.10 for all Among coinfected patients, absence of HIV suppression was the only risk factor for low muscle mass ( Table 2) . Nadir CD4 þ cell count, active alcohol consumption, active IDU, and noninvasive assessment of liver fibrosis were not associated with low muscle mass. Results were similar when FIB-4 was analyzed within models instead 
Discussion
In this study, low muscle mass was significantly more common in HIV/viral hepatitis-coinfected persons compared with HIV-monoinfected, viral hepatitismonoinfected, and uninfected persons. This finding persisted after adjustment for use of NRTIs associated with lipoatrophy among HIV-infected persons and after exclusion of those with cirrhosis as determined by APRI. Detectable HIV viremia was the main risk factor for low muscle mass in the coinfected group, suggesting there may be detrimental synergistic activity between viral hepatitis infection and uncontrolled HIV on muscle mass.
There are several potential mechanisms by which HIV/ viral hepatitis coinfection could contribute to low muscle mass. A chronically heightened inflammatory state, driven by lack of HIV virologic control [13, 50] , might impose greater metabolic demands on the body that, if unmet, could lead to muscle atrophy [51] . Direct liver injury exacerbated by HIV infection may impair cellular processes such as glycogenesis, gluconeogenesis, and protein synthesis, thereby promoting low muscle mass [52] [53] [54] [55] [56] . HIV can infect hepatic stellate cells and promote fibrogenesis [57, 58] . Indeed, HIV viremia in HIV/HCVcoinfected patients has been associated with more rapid fibrosis progression compared with HCV-monoinfected and HIV/HCV-coinfected patients with undetectable HIV RNA [57, 59] . In addition, chronic viral hepatitis could contribute to insulin resistance and the development of metabolic syndrome that already occurs in HIVinfected persons on ART, ultimately leading to steatohepatitis and further alterations in body composition [60, 61] . Finally, HIV and viral hepatitis infections are associated with alcohol and other substance abuse [62, 63] , which may contribute independently to low muscle mass in these individuals.
Persistent HIV viremia, likely mediated by ART nonadherence, was the only identifiable risk factor for low muscle mass for coinfected individuals. Absence of HIV suppression may also conceivably be a surrogate marker of social determinants, such as socioeconomic 2524 AIDS 2016, Vol 30 No 16 instability or food insecurity, that are more directly linked to low muscle mass. Alternatively, those with an inability to achieve HIV virologic suppression may harbor HIV strains with a higher replicative capacity or host-specific factors that also predispose to low muscle mass. However, if persistent HIV viremia actually was indirectly measuring these other social or host determinants, then low muscle mass would be expected to be more prevalent among HIV-monoinfected persons with uncontrolled HIVas well. Instead, the lack of associations between HIV viremia and low muscle mass in HIV monoinfection and between HIV/viral hepatitis coinfection and low muscle mass among those with HIV virologic suppression suggests that uncontrolled HIV and viral hepatitis infections actually may interact negatively to exacerbate the metabolic consequences of each.
Despite prior studies demonstrating a high prevalence of low muscle mass in cirrhosis, stage of hepatic fibrosis, determined by either APRI or FIB-4, was not associated with low muscle mass in HIV/viral hepatitis coinfection. Although this may have been driven by a low prevalence of advanced liver disease in our study sample, it also suggests that the mechanisms underlying the development of low muscle mass in HIV/viral hepatitis coinfection may not be primarily mediated by loss of hepatic function. Systemic inflammation driven by uncontrolled HIV may be a critical factor contributing to low muscle mass. Active alcohol and IDU were not determinants of low muscle mass, despite well established relationships between these substances and malnutrition [63] [64] [65] [66] [67] [68] . However, future studies should explore possible associations between low muscle mass and quantity of substance(s) used, as there may be threshold levels required before the detrimental effects of these substances on metabolic health are manifest.
These data build on prior work using the NHANES (1999-2010) demonstrating that low muscle mass was more prevalent in chronic HCV-infected persons compared with uninfected, healthy adults [13.8 vs 6.7%; OR, 2.22 (95% CI, 1.39-3.56)] in the United States [20] . The prevalence of low muscle mass by anthropometry in HIV-monoinfected (12%) and viral hepatitis-monoinfected (10%) persons, respectively, was similar to that previously observed in HCV-monoinfected individuals (14%; P ¼ 0.481 and 0.222). However, we observed a higher prevalence of low muscle mass among uninfected persons in our study (10 vs 6.7%; P < 0.001), suggesting that the uninfected group here may not be reflective of the healthy, general population as captured in the contemporaneous NHANES population. This is likely driven by the selective enrollment of individuals at high risk for HIV in the MACS and WIHS cohorts, who may also have higher rates of substance use or other conditions that independently predispose to low muscle mass. Importantly, this may explain why the associations between low muscle mass and HIV or viral hepatitis monoinfection did not reach statistical significance when compared with uninfected persons. In addition, the magnitude of association between HIV/ viral hepatitis coinfection and low muscle mass, as compared with uninfected persons in this study, may be an underestimate of the true impact of coinfection on low muscle mass.
The current study has several potential limitations. Due to the cross-sectional design, we are unable to infer causality between HIV/viral hepatitis coinfection and low muscle mass. However, low muscle mass is not likely to lead to HIV or viral hepatitis infection independent of risk behaviors controlled for in the study. Although low muscle mass was defined using anthropometric measurements, we observed a strong correlation between MUAC and fat-free mass estimated by SF-BIA in a subgroup analysis, supporting its use. Although ascites can affect the validity of BIA measurements in chronic liver disease, the impact in this study was likely minimal due to the low proportion of participants with advanced liver disease (<2%). Incorporation of MUAC measurements alongside height and weight during routine clinic visits is highly feasible, without requiring highly specialized equipment, intensive training, or invasive techniques, and may enable earlier detection of both low muscle mass and increased mortality risk in our patients [40, 69, 70] . Potential peripheral lipoatrophy from specific antiretrovirals could have confounded our results. However, this possibility was strongly mitigated by restricting our study to HIVinfected persons initiating ART after January 2000 and by controlling for residual confounding from active and/or past use of implicated drugs. Triceps skinfold thickness and handgrip strength measurements were not available in this study, preventing us from using MUAC or handgrip strength as complementary assessments of low muscle mass. However, these measurements could be feasibly obtained in the future and may enhance the clinical evaluation of low muscle mass. Lastly, there may be other factors, including physical activity indices and other medical or psychiatric comorbidities, that were not completely ascertained in this study, which may mediate the development of low muscle mass in HIV and viral hepatitis coinfection and should be explored in future studies.
In summary, HIV/viral hepatitis coinfection was associated with a substantially higher prevalence of low muscle mass compared with HIV monoinfection, HCV monoinfection, and uninfected but at-risk persons, even prior to the development of advanced liver disease. Absence of HIV suppression was a key risk factor for this outcome among coinfected patients. Future studies are needed to gain insight into the mechanisms underpinning the development of low muscle mass and further assess the impact of low muscle mass on disease progression and overall survival in HIV/viral hepatitis coinfection.
